Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niven Mehra

Showing results (61-70 of 161) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancerMaarten J van der Doelen, Pedro Isaacsson Velho, Peter H J Slootbeek, et al.
Frontiers in Immunology|January 20, 2022
Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial CancerSandra van Wilpe, Mark A J Gorris, Lieke L van der Woude, et al.
Frontiers in Oncology|June 4, 2021
Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate CancerJeroen H A Creemers, Maarten J van der Doelen, Sandra van Wilpe, et al.
Cancers|August 7, 2021
Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV MelanomaSofie H Tolmeijer, Rutger H T Koornstra, Jan Willem B de Groot, et al.
Frontiers in Oncology|November 16, 2020
High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate CancerHarm Westdorp, Jeroen H A Creemers, Inge M van Oort, et al.
European Urology Oncology|November 5, 2025
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate CancerFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
Cancer Reports (Hoboken, N.J.)|March 12, 2021
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib studyMarit A C Vermunt, Debbie G J Robbrecht, Lot A Devriese, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
<sup>68</sup>Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate CancerAnouk C de Jong, Minke Smits, Job van Riet, et al.
European Urology Open Science|January 12, 2024
Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide CohortAnke Richters, Debbie G J Robbrecht, Richard P Meijer, et al.
European Urology|June 24, 2022
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1Fred Saad, Johann de Bono, Philippe Barthélémy, et al.
Pageof 17

Showing results (61-70 of 161) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancerMaarten J van der Doelen, Pedro Isaacsson Velho, Peter H J Slootbeek, et al.
Frontiers in Immunology|January 20, 2022
Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial CancerSandra van Wilpe, Mark A J Gorris, Lieke L van der Woude, et al.
Frontiers in Oncology|June 4, 2021
Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate CancerJeroen H A Creemers, Maarten J van der Doelen, Sandra van Wilpe, et al.
Cancers|August 7, 2021
Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV MelanomaSofie H Tolmeijer, Rutger H T Koornstra, Jan Willem B de Groot, et al.
Frontiers in Oncology|November 16, 2020
High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate CancerHarm Westdorp, Jeroen H A Creemers, Inge M van Oort, et al.
European Urology Oncology|November 5, 2025
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate CancerFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
Cancer Reports (Hoboken, N.J.)|March 12, 2021
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib studyMarit A C Vermunt, Debbie G J Robbrecht, Lot A Devriese, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
<sup>68</sup>Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate CancerAnouk C de Jong, Minke Smits, Job van Riet, et al.
European Urology Open Science|January 12, 2024
Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide CohortAnke Richters, Debbie G J Robbrecht, Richard P Meijer, et al.
European Urology|June 24, 2022
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1Fred Saad, Johann de Bono, Philippe Barthélémy, et al.
Pageof 17